vTv Therapeutics Inc.

VTVT • Biotechnology

$33.35

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$413.85M

Crecimiento

-100.0%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0Liquidez saludable · 13.54Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 13 ago 2026, 12:56 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$33.35

Change0.00%

Shares Out12.41M

Market Cap$413.85M

Enterprise Value$327.21M

52W Range14.55 - 44.00

Beta0.29

P/E-87.02

P/S11.23

P/B5.26

P/FCF-54.40

EV/Sales8.88

Price$33.35

Change0.00%

Shares Out12.41M

Market Cap$413.85M

Enterprise Value$327.21M

52W Range14.55 - 44.00

Beta0.29

P/E-87.02

P/S11.23

P/B5.26

P/FCF-54.40

EV/Sales8.88

EV/EBITDA-45.06

EV/FCF-43.01

Earnings Yield-1.15%

FCF Yield-1.84%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio13.54

Quick Ratio13.54

Revenue 5Y-100.00%

Target$42.00

Target Upside25.94%

Target Median$42.00

Target Range42.00 - 42.00

Volume49.42K

Avg Volume65.60K

EPS Surprise1.31

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

70/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

60/100

Por qué este puntaje▼

Nivel de deuda manejable · 0Liquidez saludable · 13.54Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

VTVT

Analyst sentiment

Based on 14 analyst votes · 2026-09-05

75/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-13

Bajo

$42.00

Promedio

$42.00

Mediana

$42.00

Alto

$42.00

Resumen de la compañía

IPO: 7/30/2015

Industria: Biotechnology

P/B i: 5.26

Deuda / Patrimonio i: 0.00

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje14 / 20

Deuda / Patrimonio: 0.00

Ratio corriente: 13.54

Ratio rápido: 13.54

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Phillips Anne M.

Transacción: 06/26/2026

COMPRA

Cambio

+6,000

Precio

$35.08

Presentación

06/29/2026

Tipo

COMPRA

Al-Marzooqi Fahed

Transacción: 06/26/2026

COMPRA

Cambio

+6,000

Precio

$35.08

Presentación

06/29/2026

Tipo

COMPRA

AKKARAJU SRINIVAS

Transacción: 06/26/2026

COMPRA

Cambio

+6,000

Precio

$35.08

Presentación

06/29/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Phillips Anne M.	COMPRA	+6,000	$35.08	06/26/2026	06/29/2026
Al-Marzooqi Fahed	COMPRA	+6,000	$35.08	06/26/2026	06/29/2026
AKKARAJU SRINIVAS	COMPRA	+6,000	$35.08	06/26/2026	06/29/2026
SPIEGELMAN DANIEL K	COMPRA	+6,000	$35.08	06/26/2026	06/29/2026
BAKER BROS. ADVISORS LP	COMPRA	+6,000	$35.08	06/26/2026	06/29/2026
SEKHRI PAUL J	COMPRA	+140,000	$36.92	02/17/2026	02/18/2026
Tung Michael Stephen	COMPRA	+44,969	$36.92	02/17/2026	02/18/2026
AKKARAJU SRINIVAS	COMPRA	+106,000	$15.27	09/22/2025	09/25/2025
AKKARAJU SRINIVAS	COMPRA	+877,214	$0.01	09/22/2025	09/25/2025
AKKARAJU SRINIVAS	COMPRA	+983,214	$22.71	09/22/2025	09/25/2025
BAKER BROS. ADVISORS LP	COMPRA	+4,308	$15.27	09/03/2025	09/05/2025
BAKER BROS. ADVISORS LP	COMPRA	+221,452	Not reported	09/03/2025	09/05/2025
BAKER BROS. ADVISORS LP	COMPRA	+217,144	$0.01	09/03/2025	09/05/2025
AKKARAJU SRINIVAS	COMPRA	+655,523	$22.71	09/03/2025	09/05/2025
AKKARAJU SRINIVAS	COMPRA	+655,523	$0.01	09/03/2025	09/05/2025
Al-Marzooqi Fahed	COMPRA	+4,000	$16.59	06/10/2025	06/12/2025
Phillips Anne M.	COMPRA	+4,000	$16.59	06/10/2025	06/12/2025
AKKARAJU SRINIVAS	COMPRA	+4,000	$16.59	06/10/2025	06/12/2025
SPIEGELMAN DANIEL K	COMPRA	+4,000	$16.59	06/10/2025	06/12/2025
BAKER BROS. ADVISORS LP	COMPRA	+4,000	$16.59	06/10/2025	06/12/2025

Sobre la compañía

vTv Therapeutics Inc.

vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.

Fuente - Link

Competidores

CRVO FBIO GANX HOWL INKT IOBT NRXP OSTX OTLK SPRB

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

vTv Therapeutics to Participate in September Investor Conferences

HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in September:

GlobeNewsWire

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout Company to host Key Opinion Leader (KOL) event in the fourth quarter of 2026 highlighting cadisegliatin and its potential in people with T1D HIGH POINT, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

GlobeNewsWire

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 23,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 12,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-13	0.34	1.65	1.31
2026-03-10	-0.98	-0.58	0.4
2025-11-06	-0.97	-1.08	-0.11
2025-08-12	-0.85	-0.92	-0.07
2025-05-15	-0.73	-0.77	-0.04
2025-03-20	-0.87	-0.55	0.32
2024-11-12	-3.6	-0.88	2.72
2024-08-08	-3.2	-0.81	2.39
2024-05-09	-3.2	-1.17	2.03
2024-03-13	-2.8	-1.67	1.13
2023-11-09	-3.2	-3.2	0
2023-08-11	-0.07	-2.8	-2.73